Jane Street Group LLC grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 325.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 164,911 shares of the biotechnology company's stock after buying an additional 126,135 shares during the quarter. Jane Street Group LLC owned 0.33% of REGENXBIO worth $1,275,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in RGNX. JPMorgan Chase & Co. increased its stake in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of REGENXBIO by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock valued at $9,054,000 after purchasing an additional 21,234 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of REGENXBIO by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after buying an additional 5,574 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in REGENXBIO in the 4th quarter worth approximately $3,865,000. Finally, Norges Bank bought a new stake in REGENXBIO in the 4th quarter worth approximately $3,474,000. 88.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have commented on the stock. HC Wainwright decreased their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. The Goldman Sachs Group decreased their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Morgan Stanley lifted their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Finally, Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $31.63.
Read Our Latest Analysis on REGENXBIO
Insider Buying and Selling at REGENXBIO
In other news, Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the transaction, the director now owns 475,103 shares of the company's stock, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.79% of the company's stock.
REGENXBIO Price Performance
NASDAQ:RGNX traded down $0.15 during trading hours on Monday, hitting $9.71. The company had a trading volume of 645,180 shares, compared to its average volume of 882,966. The stock has a 50-day moving average price of $7.85 and a 200 day moving average price of $7.98. The company has a market capitalization of $487.05 million, a PE ratio of -1.93 and a beta of 1.11. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $15.39.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. Analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
